Company: PCRX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001104659-25-041219
Chunk: 107

Company: Pacira BioSciences, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 107
---
 | ​ | ​ | ​ |
| 2014 ESPP                                               | ​ | ​ | ​                                                                               | ​ |            — | ​ | ​ | ​ | ​ | ​                                                                 | ​ | —        | ​ | ​ | ​ | ​ | ​                                                                                                                                         | ​ |      314,929 | ​ | ​ | ​ |
| Equity compensation plans not approved by stockholders: | ​ | ​ | ​                                                                               | ​ |            ​ | ​ | ​ | ​ | ​ | ​                                                                 | ​ | ​        | ​ | ​ | ​ | ​ | ​                                                                                                                                         | ​ |            ​ | ​ | ​ | ​ |
| 2014 Inducement Plan(4)                                 | ​ | ​ | ​                                                                               | ​ | 1,387,332(2) | ​ | ​ | ​ | ​ | ​                                                                 | $ | 22.17(2) | ​ | ​ | ​ | ​ | ​                                                                                                                                         | ​ |   125,107(3) | ​ | ​ | ​ |
| Total                                                   | ​ | ​ | ​                                                                               | ​ |    9,615,346 | ​ | ​ | ​ | ​ | ​                                                                 | $ | 42.95(1) | ​ | ​ | ​ | ​ | ​                                                                                                                                         | ​ | 2,512,350(3) | ​ | ​ | ​ |

(1) Includes 5,844,006 shares subject to outstanding stock options and 2,384,008 shares subject to unvested RSUs. The weighted-average exercise price for the 2011 Plan only relates to the outstanding stock options. (2) Includes 1,001,612 shares subject to outstanding stock options and 385,720 shares subject to unvested RSUs. The weighted-average exercise price for the 2014 Inducement Plan only relates to the outstanding stock options. (3) Awards issuable under the 2011 Plan and the 2014 Inducement Plan include stock options, SARs, restricted stock, RSUs and other stock-based awards. (4) The material terms of the 2014 Inducement Plan are substantially similar to the 2011 Plan.

Pacira BioSciences, Inc. 2025 Proxy Statement | 109

TABLE OF CONTENTS

| ​ | ​ | STOCKOWNERSHIPINFORMATION | ​ |

| ​ | ​                           | ​ | ​ | ​                                   | ​ | ​ | ​            | ​ | ​